4 active not recruiting. 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Active not recruiting 4 |
Follow Myelofibrosis: new trials by email Literature Review of Myelofibrosis trials Research Report on Myelofibrosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment Imetelstat, Best Available Therapy (BAT) - Myelofibrosis | Phase 3 | Active not recruiting | Geron Corporation | 327 | 2021-04-12 | 2026-07-08 |
| Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2) Pelabresib, Ruxolitinib, Placebo - Myelofibrosis, Primary Myelofibrosis | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 430 | 2021-04-09 | 2026-07-17 |
| Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis Selinexor, Placebo, Ruxolitinib - Myelofibrosis | Phase 3 | Active not recruiting | Karyopharm Therapeutics Inc | 353 | 2021-03-11 | 2026-11-04 |
| An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions ACE-536, Placebo - Myeloproliferative Disorders, Myelofibrosis | Phase 3 | Active not recruiting | Celgene | 313 | 2021-02-25 | 2026-07-16 |
Primary Myelofibrosis (4) · Myeloproliferative Disorders (3) · Anemia (1) · Polycythemia (1) · Thrombocytosis (1)
Bone Marrow Diseases (4) · Hematologic Diseases (4) · Hemic and Lymphatic Diseases (4) · Blood Platelet Disorders (1) · Myeloproliferative Disorders (1)
ruxolitinib (2) · GRN163L peptide (1) · imetelstat (1) · luspatercept (1) · selinexor (1)
Celgene (1) · Geron Corporation (1) · Karyopharm Therapeutics Inc (1) · Novartis Pharmaceuticals (1)
Australia (4) · Belgium (4) · France (4) · Germany (4) · Hungary (4) · Israel (4) · Italy (4) · Poland (4) · South Korea (4) · Spain (4) · United Kingdom (4) · United States (4) · Austria (3) · Canada (3) · Czechia (3)
Joe Eid (1)
PMID 35510486, PMID 35950489, PMID 39911057, PMID 40065169, PMID 41785311, PMID 42227656
2023 (3)